Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.
Siavash ForoughiJeanne TiePeter GibbsAntony Wilks BurgessPublished in: Growth factors (Chur, Switzerland) (2019)
The discovery of epidermal growth factor (EGF) and its receptor (EGFR) revealed the connection between EGF-like ligands, signaling from the EGFR family members and cancer. Over the next fifty years, analysis of EGFR expression and mutation led to the use of monoclonal antibodies to target EGFR in the treatment of metastatic colorectal cancer (mCRC) and this treatment has improved outcomes for patients. The use of the RAS oncogene mutational status has helped to refine patient selection for EGFR antibody therapy, but an effective molecular predictor of likely responders is lacking. This review analyzes the potential utility of measuring the expression, levels and activation of EGF-like ligands and associated processes as prognostic or predictive markers for the identification of patient risk and more effective mCRC therapies.
Keyphrases
- epidermal growth factor receptor
- growth factor
- tyrosine kinase
- small cell lung cancer
- metastatic colorectal cancer
- advanced non small cell lung cancer
- poor prognosis
- squamous cell carcinoma
- end stage renal disease
- small molecule
- case report
- chronic kidney disease
- binding protein
- ejection fraction
- weight loss
- single cell
- type diabetes
- combination therapy
- mesenchymal stem cells
- young adults
- risk assessment
- wound healing
- squamous cell
- patient reported
- lymph node metastasis
- childhood cancer